RNS Hotlist with Zak Mir, 5th January 2022, ORCP, VAL, BLU, NTOG, STX, SRB & ORR via Vox Markets

The award for RNS of the day, at least in terms of transformational implications, most likely goes to Oracle Power (ORCP), the international natural resources project developer.

By Zak Mir

It said that positive assay results have been received from the maiden drilling programme at the Northern Zone Gold Project, located 25km east of Kalgoorlie in Western Australia. This first phase of Reverse Circulation successfully targeted gold mineralisation within a series of stacked porphyry intrusion. The key here is an Exploration Target based on historical results and the results of the recent seven drill holes indicates 200-250Mt at 0.4-0.6g/t Au for 2.5 to 4.8Moz Gold.

ValiRx (VAL), a life science company has entered into a Service Agreement with TheoremRx Inc., to enable ValiRx to work with TheoremRx to engage with Clinical Research Organisations and supporting vendors for the next clinical trial of VAL201. This Service Agreement allows ValiRx and TheoremRx to enter into a sub-license to enable TheoremRx to develop VAL201 in the field of oncology. Completion of the sub-license is subject to the successful fundraise by TheoremRx.

A badge of honour on the AIM market is when a company is asked to issue a speeding ticket RNS. This is the case with Blue Star Capital (BLU), the investing company as it noted the recent rise in the company’s share price. The Board confirms that it is not aware of a reason for this increase. The ideal scenario after such a RNS is that the share price continues to rocket, if only to stress out the Nomad still further.

Nostra Terra (NTOG), the oil & gas exploration and production company with assets in Texas, USA, provided its growth plans for 2022. The company said it is cashflow positive to the corporate level and has multiple wells planned to drill throughout the year, all funded without need for dilution. It anticipates these wells having a strong contribution to cashflow after allowing for further investment for growth in other areas, with the potential of significant upside potential through exploring a large, gas-prone acreage position in a very prospective region in Tunisia at a time when the gas market is very strong.

It would appear that Shield Therapeutics (STX), a commercial-stage speciality pharmaceutical company is starting 2022 on the front foot. It announced that it has entered into an exclusive licence agreement for Accrufer® with KYE Pharmaceuticals Inc. in Canada. Shield will receive an upfront payment of £150,000 and is eligible to receive £850,000 in development and sales milestones.For the term of the agreement, Shield will also receive double-digit royalties on net sales of Accrufer®.

Serabi Gold (SRB), the Brazilian-focused gold mining and development company, provided assay results from recent surface and underground exploration drillholes into the Chico da Santa sector, as well as the first results into the newly discovered Pele sector at the Palito Gold Mine, Para State, northern Brazil. This exploration programme is targeting strike and resource extension of the established Ipe and Mongo veins with results confirming extension along strike and at depth. The highlight for SRB is that the step-out exploration drilling programme has recorded multiple high grade intercepts into the ‘Chico da Santa’ veins at Palito. The company said that it is exciting to see intercepts which extend the veins well beyond the current mine limits, both along strike and at depth. The results suggest a possibility of improving grades and payability with depth, which bodes well for the future.

Oriole Resources (ORR), the AIM-quoted exploration company focused on West Africa, announced results from a recently completed soil sampling programme at its 90%-owned Bibemi gold project in Cameroon. The results have returned up to 271 parts per billion gold and have confirmed continuity of the Bakassi Zone 1 prospect by c.3 kilometres to the southwest, connecting it with the Lawa West prospect.

Read More

Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.

Linking Shareholders and Executives :Share Talk

If anyone reads this article found it useful, helpful? Then please subscribe www.share-talk.com or follow SHARE TALK on our Twitter page for future updates. Terms of Website Use All information is provided on an as-is basis. Where we allow Bloggers to publish articles on our platform please note these are not our opinions or views and we have no affiliation with the companies mentioned
Share Talk
Share via
Copy link
Malcare WordPress Security